Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)
Recruitment status was Not yet recruiting
This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.
Pervasive Developmental Disorder
Drug: low dose naltrexone
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD|
- play observation
- Autism Behavior Checklist (ABC) questionnaire
Fifty children aged three to six years will be recruited for the study. They will be randomly assigned to receive either LDN or placebo for two months after which the treatment groups will be switched over. Assessments of functioning will be obtained from a video-taped play session, and by parent and teacher questionnaires at baseline, after two months and after four months.
|Contact: David S Wilensky, MDfirstname.lastname@example.org|
|Jerusalem Institute for Child Development||Not yet recruiting|
|Principal Investigator:||David S Wilensky, MD||Jerusalem Institute for Child Development|